

Disclosure continued.

Armstrong has served as a research investigator and/or scientific advisor to AbbVie, Almirall, Arcutis Biotherapeutics, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Dermira, EPI, Incyte Corporation, Janssen, LEO Pharma A/S, Lilly, Modmed, Nimbus, Novartis, Ortho Dermatologics, Pfizer, Regeneron, Sanofi, Sun Pharma, and UCB. Augustin has served as a consultant, lecturer, and researcher for, and/or has received research grants from companies manufacturing drugs for psoriasis from, AbbVie, Almirall, Amgen, Bayer, Beiersdorf, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Centocor, Dermira, Eli Lilly, Galderma, Genzyme, GlaxoSmithKline, Hexal, Incyte, Janssen, LEO Pharma, Medac, Menlo, MSD, Mylan B.V., Novartis, Pfizer, Regeneron, Sandoz, Sanofi, Stallergenes, Trevi, and UCB. Bauer has been a speaker/advisor/investigator and/or received research funding from AbbVie, Almirall, Amgen, AstraZeneca, Biofrontera, Blueberry Therapeutics, Celldex, Centogene, Galderma, Genentech, Gilead, Incyte, LEO Pharma, Lilly, L'Oréal, Novartis, Sanofi, Regeneron, and Takeda. Bissonnette has been an advisory board member, consultant, speaker and/or investigator for, and receives honoraria and/or grants from, AbbVie, Amgen, Apogee, Arcutis, Asana BioSciences, Bellus Health, BioMimetix, Bluefin Biomedicine, Boehringer-Ingelheim, Boston, CARA Therapeutic, Clexio, Dermavant, Eli Lilly, Escient, Evidera, Fresh Tracks (Brickell), Galderma, GlaxoSmithKline, Incyte, Inmagene Bio, Janssen, LEO Pharma, Merck, Novartis, Opsidio, Pfizer, RAPT Therapeutic, Regeneron, Sanofi, Target RWE, Vyne Therapeutics, and Zencor. Blauvelt has served as a speaker (received honoraria) for AbbVie, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Regeneron, and Sanofi; served as a scientific adviser (received honoraria) for AbbVie, Abcentra, Aclaris, Affibody, Aligos, Almirall, Alumis, Amgen, Anaptysbio, Arcutis, Arena, Aslan, Athenex, Bluefin Biomedicine, Boehringer Ingelheim, Bristol-Myers Squibb, Cara Therapeutics, Dermavant, EcoR1, Eli Lilly and Company, Escient, Evelo, Evommune, Forte, Galderma, HighlightII Pharma, Incyte, InnoventBio, Janssen, Landos, LEO Pharma, Merck, Novartis, Pfizer, Rani, Rapt, Regeneron, Sanofi Genzyme, Spherix Global Insights, Sun Pharma, TLL Pharmaceutical, TrialSpark, UCB Pharma, Union, Vibliome, and Xencor; and has acted as a clinical study investigator (institution has received clinical study funds) for AbbVie, Acelyrin, Almirall, Alumis, Amgen, Arcutis, Athenex, Boehringer Ingelheim, Bristol-Myers Squibb, Concert, Dermavant, Eli Lilly and Company, Evelo, Evommune, Galderma, Incyte, Janssen, Leo, Merck, Novartis, Pfizer, Regeneron, Sun Pharma, and UCB Pharma. Butler has been an advisor for LEO Pharma, Sanofi, and Galderma; and an investigator for Pfizer and AbbVie. Cohen has been a consultant and receives honoraria from Ferndale Laboratories, Medimetriks, LEO Pharma, Union Chimique Belge, Novartis (past), SFJ Pharmaceuticals (past), FIDE, and Cosmetic Ingredient Review; has stock or stock options for Kadmon (past), Evommune, and Timber; and serves on the board of directors for Kadmon (past), Timber, and Evommune Demira (past). Ehst has received fees/honoraria/royalties as an advisory board member, contributor, and/or consultant for AbbVie, Arcutis Biotherapeutics, Dermavant Sciences, Eli Lilly, Evelo Biosciences, Evommune, Janssen Biotech, LEO Pharma, Novartis, Ortho Dermatologics, Proivant, and UCB; received speaking fees from AbbVie, Dermavant Sciences, Eli Lilly, Incyte, LEO Pharma, Novartis, National Psoriasis Foundation, Regeneron, Up-To-Date, Ortho Dermatologics, and Sanofi-Genzyme; and has received institutional funding as an investigator for AbbVie, Aclaris Therapeutics, Almirall, Alumis, Amgen, Arcutis Biotherapeutics, BMS, Celgene, Concert Pharmaceuticals, Dermavant Sciences, Demira, Eli Lilly, Evelo Biosciences, Incyte, Janssen Biotech, Kymab, LEO Pharma, Novan, Novartis, Pfizer, Regeneron, Sanofi-Genzyme, Sun Pharma, UCB, and Ventyx Biosciences. Giménez-Arnau has been a speaker and/or advisor for, and/or has received research funding from, Almirall, Amgen, AstraZeneca, Avene, Blueprint, Celldex, Escient Pharmaceuticals, Genentech, GSK, Harmonic Bio, Instituto Carlos III- FEDER, Jaspers, LEO Pharma A/S, Menarini, Mitsubishi Tanabe Pharma, Noucor, Novartis, Sanofi-Regeneron, Septerna, Servier, Thermo Fisher Scientific, and Uriach Pharma. Gooderham has been an investigator, speaker and/or advisor for AbbVie, Acelyrin, Amgen, Akros, AnaptysBio, Arcutis, Aristeia, ASLAN Pharmaceuticals, Apogee, Bausch Health, BMS, Boehringer Ingelheim, Cara Therapeutics, Celgene, Dermira, Dermavant, Eli Lilly, Galderma, Inmagene Biopharmaceuticals, Incyte, Janssen, LEO Pharma, MedImmune, Meiji Seika Pharma, Moonlake, Nimbus, Novartis, Pfizer, Regeneron, Reistone Biopharma, Roche, Sanofi Genzyme,

Sun Pharma, Tarsus, Takeda Pharmaceuticals, UCB, and Ventyx. Lio has served in a consulting or advisory role for LEO Pharma. Pezzolo has been a consultant, clinical trial investigator, and speaker for LEO Pharma A/S, Abbvie, Pfizer, Novartis, Sanofi Genzyme, Galderma, Boehringer Ingelheim, and Janssen. Serra-Baldrich has received personal fee payments and travel support from Abbvie, Lilly, Sanofi, Novartis, Pfizer, Galderma, and LEO Pharma. Thaçi has served as an investigator and/or consultant/adviser for AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celltrion, Eli Lilly, Galderma, Janssen-Cilag, LEO Pharma A/S, L'Oreal, Meiji, NewBridge, Novartis, Regeneron, Sanofi, Pfizer, Target-RWE, UCB, and Vichy; and has received grants from AbbVie, LEO Pharma A/S, and Novartis. Yu has received fees/honoraria/royalties as an advisory board member for Arcutis, Incyte, Sanofi, LEO, Astria Therapeutics, and O'Glancee; and as a consultant for Dermavant, iRhythm, and the National Eczema Association.